课题基金 / 基金详情

肝癌细胞内质网应激诱导的NAT10表达对RNA乙酰化ac4C修饰靶基因的筛选与鉴定及其对药物敏感性的影响

批准号:
82072751
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
孙国平
依托单位:
学科分类:
肿瘤治疗抵抗
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
孙国平

项目摘要

结项摘要

孙国平的其他基金

相似基金

相关文献

中文摘要
内质网应激(ERS)介导肝癌耐药机制尚不明确。NAT10介导RNA乙酰化ac4C修饰是目前研究热点,但与ERS相关的耐药关系未见报道。我们前期发现肝癌细胞ERS后NAT10染色质开放性、转录组及蛋白表达均明显增加,抑制NAT10可增加药物敏感性,提示ERS相关耐药与NAT10介导的RNA乙酰化ac4C修饰有关。本项目将首先明确肝癌细胞ERS诱导NAT10表达的上游调控机制,然后在细胞水平上,利用acRIP-seq分析转录组ac4C修饰位点,联合LongRNA-seq和Ribo-seq系统发现NAT10作用靶点和调控网络,预测并验证与耐药相关的靶基因及信号通路。通过调控相关靶基因观察药物敏感性变化,阐明相关信号通路。在此基础上,通过荷瘤小鼠模型研究NAT10介导的RNA乙酰化ac4C修饰对肝癌药物敏感性的影响。本研究将进一步阐明肝癌ERS相关耐药分子机制,有望发现肝癌药物治疗作用新靶点。
英文摘要
It is well believed that endoplasmic reticulum stress plays an important role in drug resistance in hepatocellular carcinoma (HCC).However, the molecular and cellular mechanisms underlying drug resistance induced by endoplasmic reticulum stress are largely unknown.Currently,N4-acetylcytidine (ac4C) as an mRNA modification that is catalyzed by the acetyltransferase NAT10 is becoming a hot topic in cancer area. However, the molecular and cellular mechanisms underlying the relationship between RNA ac4C and drug resistance induced by endoplasmic reticulum stress are still needed further investigation.Our previous studies found that NAT10 in hepatoma cells significantly changed after ERS stimulation using ATAC-seq , transcriptome sequencing platform and Western-blot.Inhibition of NAT10 can increase drug sensitiveness.Base on these finding, we propose the hypothesis that drug resistance mediated by ERS is closely related to RNA ac4C catalyzed by the acetyltransferase NAT10. To test this hypothesis, we first clarify the upstream mechanism of NAT10 expression induced by ERS in hepatocellular carcinoma cells.We will use acRIP-seq platform to perform ac4C Mapping in Poly(A) RNA.Then we used methods such as LongRNA-seq and Ribo-seq to predicted the functional of target RNA ac4C catalyzed by the acetyltransferase NAT10 induced by endoplasmic reticulum stress in drug resistance.The functions of target RNA ac4C catalyzed by the acetyltransferase NAT10 and related signal pathways will be confirmed.Lastly, gene editing of hepatoma cells on tumor-bearing mouse models will be performed to test the effects of RNA ac4C catalyzed by the acetyltransferase NAT10 induced by endoplasmic reticulum stress and drug sensitiveness.The proposed studies above not only could further precisely demonstrate the molecular mechanisms of drug resistance induced by endoplasmic reticulum stress but also provide solid evidence and basis for developing novel drug target in the future.
内质网应激(ERS)介导肝癌耐药机制尚不明确。NAT10介导RNA乙酰化ac4C修饰是目前研究热点,但与ERS相关的耐药关系未见报道。NAT10在肝癌中的表达显著上调。临床上,NAT10高表达与预后不良和病毒性肝炎及肝硬化有关。细胞和动物实验结果表明,NAT10在体内增强了肝癌细胞ERS和ERS状态下肝癌细胞的转移能力和仑伐替尼凋亡抵抗。在机制上,我们发现NAT10可能上调HSP90AA1 mRNA ac4C的修饰水平,维持HSP90AA1的稳定性,并上调HSP90AA1的表达,进一步促进ERS肝癌细胞转移和仑伐替尼凋亡抵抗。本研究提出了一种新的NAT10介导的mRNA ac4C修饰调控肿瘤转移机制。此外,我们还证实NAT10-HSP90AA1对ERS肝癌细胞转移和抗药性的调节作用。因此,我们可能为HCC预防和治疗提供了一种新的策略。
内质网应激相关超级增强子对肝癌细胞自噬的调控及其对化疗药物敏感性的影响
  • 批准号:
    81872047
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2018
  • 负责人:
    孙国平
  • 依托单位:
内质网应激诱导的exosomes释放对肿瘤微环境的调控及其在肝癌免疫逃逸中的作用
  • 批准号:
    81572430
  • 项目类别:
    面上项目
  • 资助金额:
    68.0万元
  • 批准年份:
    2015
  • 负责人:
    孙国平
  • 依托单位:
肝癌细胞内质网应激耐受特异miRNAs鉴定及其对化疗敏感性影响的机制
  • 批准号:
    81272739
  • 项目类别:
    面上项目
  • 资助金额:
    70.0万元
  • 批准年份:
    2012
  • 负责人:
    孙国平
  • 依托单位:
肝癌细胞逃避内质网应激介导的凋亡的分子机制及丹皮酚的干预作用
  • 批准号:
    81071986
  • 项目类别:
    面上项目
  • 资助金额:
    36.0万元
  • 批准年份:
    2010
  • 负责人:
    孙国平
  • 依托单位:
国内基金
海外基金